Loading clinical trials...
Loading clinical trials...
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
GSK Investigational Site
Loma Linda, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Ann Arbor, Michigan, United States
GSK Investigational Site
Southgate, Michigan, United States
GSK Investigational Site
Jefferson City, Missouri, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Mexico City, Mexico
Start Date
March 1, 2008
Primary Completion Date
April 1, 2011
Completion Date
January 1, 2015
Last Updated
January 29, 2016
68
ACTUAL participants
Lapatinib and Capecitabine
DRUG
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions